- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01896193
Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection
May 7, 2015 updated by: Gilead Sciences
A Phase 3b, Multicenter, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naïve Adults With Genotype 1 and 3 Chronic HCV Infection.
This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir plus ribavirin administered for 16 weeks and 24 weeks in participants with chronic genotype 1 (GT1) or genotype 3 (GT3) hepatitis C virus (HCV) infection.
Study Overview
Study Type
Interventional
Enrollment (Actual)
127
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Moscow, Russian Federation
- Central Clinical Hospital of the Russian Academy of Sciences
-
Moscow, Russian Federation
- Central Scientific and Research Institute of Epidemiology of Rospotrebnadzor
-
Moscow, Russian Federation
- Central Scientific Research Institution of Gastroenterology of Moscow Healthcare Department
-
Moscow, Russian Federation
- City Clinical Hospital 24
-
Moscow, Russian Federation
- Clinical Diagnostics and Research Center of Federal Bedgetary Institution
-
Moscow, Russian Federation
- Infectious Clinical Hospital No. 1
-
Moscow, Russian Federation
- Institute of Nutrition of Academy of Sciences
-
Moscow, Russian Federation
- Institution of Healthcare of Sverdlovsk Region
-
Moscow, Russian Federation
- Institution of High Professional Education First Moscow State Medical University
-
Moscow, Russian Federation
- Institution of Tumen Region
-
Moscow, Russian Federation
- Krasnoyarsk Regional Center for Prevention and Control of AIDS and Infectious Diseases
-
Moscow, Russian Federation
- Scientific Research Institution of Emergency Care n.a. N.V. Sclifosovskiy of Moscow
-
Moscow, Russian Federation
- Stavropol State Medical University of Ministry of Healthcare
-
Saint-Petersburg, Russian Federation
- Medical Military Academy n.a. S.M. Kirov
-
Saint-Petersburg, Russian Federation
- Saint-Petersburg Center for Prevention and Control of AIDS and Infectious Diseases
-
Samara, Russian Federation
- Medical Company Hepatolog
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Confirmed chronic genotype 1 or 3 HCV infection
- HCV treatment-naive
- Individuals will have cirrhosis status assessment; liver biopsy may be required.
- Screening laboratory values within predefined thresholds
- Use of two effective contraception methods if female of childbearing potential or sexually active male
Exclusion Criteria:
- Pregnant or nursing female or male with pregnant female partner
- Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
- Contraindication to ribavirin therapy
- Excessive alcohol ingestion as defined by protocol
- History of solid organ transplantation
- Current or prior history of clinical hepatic decompensation
- History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SOF+RBV 16 Weeks
SOF+RBV for 16 weeks
|
Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Other Names:
Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
|
Experimental: SOF+RBV 24 Weeks
SOF+RBV for 24 weeks
|
Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Other Names:
Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)
Time Frame: Posttreatment Week 12
|
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.
|
Posttreatment Week 12
|
Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
Time Frame: Up to 24 weeks
|
The percentage of participants permanently discontinuing any study drug due to an adverse event was summarized.
|
Up to 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
Time Frame: Posttreatment Weeks 4 and 24
|
SVR4 and SVR 24 were defined as HCV RNA < LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.
|
Posttreatment Weeks 4 and 24
|
Percentage of Participants Experiencing On-treatment Virologic Failure
Time Frame: Up to 24 weeks
|
On-treatment virologic failure was defined as
|
Up to 24 weeks
|
Percentage of Participants Experiencing Virologic Relapse
Time Frame: Up to Posttreatment Week 12
|
Virologic relapse was defined as confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA < LLOQ at last on-treatment visit.
|
Up to Posttreatment Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Kathryn Kersey, MSc, Gilead Sciences
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (Actual)
April 1, 2014
Study Completion (Actual)
June 1, 2014
Study Registration Dates
First Submitted
July 2, 2013
First Submitted That Met QC Criteria
July 8, 2013
First Posted (Estimate)
July 11, 2013
Study Record Updates
Last Update Posted (Estimate)
May 29, 2015
Last Update Submitted That Met QC Criteria
May 7, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GS-US-334-0119
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
Sohag UniversityRecruiting
Clinical Trials on SOF
-
McMaster UniversityAgency for Healthcare Research and Quality (AHRQ); Grading of Recommendations...Completed
-
Sanjay Gandhi Postgraduate Institute of Medical...Ram Manohar Lohia Institute of Medical Sciences, LucknowTerminated
-
Humanity & Health Medical Group LimitedWithdrawnHCV InfectionHong Kong
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical UniversityRecruitingChronic Hepatitis C InfectionChina
-
Gilead SciencesTerminatedHepatitis C Virus InfectionFrance, Spain, United States, Australia, Canada, Germany, United Kingdom, Italy, New Zealand, Puerto Rico
-
Kirby InstituteCompleted
-
Humanity and Health Research CentreBeijing 302 HospitalCompletedChronic Hepatitis C InfectionChina
-
Humanity and Health Research CentreUniversity of Maryland; Emory University; Beijing 302 HospitalWithdrawn
-
Stanford UniversityGilead SciencesCompleted
-
Gilead SciencesCompletedHepatitis C Virus InfectionUnited States, Puerto Rico